Clinical Trials Using DOT1L Inhibitor EPZ-5676
Clinical trials are research studies that involve people. The clinical trials on this list are studying DOT1L Inhibitor EPZ-5676. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Pinometostat with Standard Chemotherapy in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
This phase Ib / II trial studies the side effects and best dose of pinometostat and how well it works with standard chemotherapy in treating patients with newly diagnosed acute myeloid leukemia and a type of genetic mutation called MLL gene rearrangement. Pinometostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in standard chemotherapy, such as daunorubicin hydrochloride and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pinometostat with standard chemotherapy may work better at treating acute myeloid leukemia.
Location: 2 locations
Pinometostat and Azacitidine in Treating Patients with Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia with 11q23 Rearrangement
This phase Ib / II trial studies the side effects and best dose of pinometostat when given together with azacitidine and to see how well it works in treating patients with acute myeloid leukemia that has come back, does not respond to treatment, or is newly diagnosed, with an 11q23 rearrangement. Pinometostat and azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Location: Memorial Sloan Kettering Cancer Center, New York, New York